Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 409 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable insulin Clear all
Not listed Not applicable Interventional

Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency

NCT01804413
View directory record Official record
Conditions
Adults Growth Hormone Deficiency.
Interventions
Pegvisomant, Regular insulin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 23, 2026, 8:55 AM EDT
Completed Not applicable Interventional Results available

PRP vs PRP Plus IGF for Patellar Tendinosis

NCT04350827
View directory record Official record
Conditions
Tendinopathy, Patellar Ligament, Platelet-Rich Plasma
Interventions
Platelet Rich Plasma, Platelet Rich Plasma plus IGF
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 23, 2026, 8:55 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

NCT00900146
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canakinumab, Metformin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 23, 2026, 8:55 AM EDT
Completed Phase 2 Interventional

21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus

NCT03156361
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
HDV insulin lispro 100 UNIT/mL, Insulin Lispro 100 Units/mL
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 23, 2026, 8:55 AM EDT
Recruiting Phase 4 Interventional

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

NCT06445946
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
Metformin, Insulin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
26
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 8:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes

NCT00727220
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
1 Year to 5 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 23, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

NCT00715624
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin, Pen auto-injector
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 23, 2026, 8:55 AM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

NCT07076199
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin icodec, Insulin glargine, Insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
103
States / cities
Cullman, Alabama • Concord, California • Escondido, California + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 8:55 AM EDT
Completed Not applicable Interventional Results available

Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles

NCT01231984
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Escondido, California • Atlanta, Georgia • Springfield, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

NCT00856986
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, insulin detemir, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 84 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
60
States / cities
Alexander City, Alabama • Birmingham, Alabama • Encino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 23, 2026, 8:55 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT07560150
View directory record Official record
Conditions
Pharmacokinetics, Pharmacodynamics, Insulin Aspart
Interventions
I004, NovoLog
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 8:55 AM EDT
Completed Phase 1 Interventional

PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes

NCT02506647
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Gan & Lee insulin glargine followed by Lantus, Lantus followed by Gan & Lee insulin glargine
Drug
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 23, 2026, 8:55 AM EDT
Terminated Not applicable Interventional

Connected Pens for Diabetes Study

NCT03830216
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Connected insulin pen and smartphone app, Inactive connected insulin pen without smartphone app
Device
Lead sponsor
Companion Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 23, 2026, 8:55 AM EDT
Active, not recruiting Phase 2 Interventional

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Frexalimab, Placebo, Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 35 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 8:55 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

NCT02018627
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Xeris glucagon, Lilly glucagon
Drug
Lead sponsor
Steven J. Russell, MD, PhD
Other
Eligibility
21 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 23, 2026, 8:55 AM EDT
Not listed Not applicable Interventional

Inpatient Self Monitoring and Administration Study (ISMAS)

NCT00506272
View directory record Official record
Conditions
Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Interventions
Self blood glucose monitoring and insulin administration, Standard care
Procedure
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 23, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration

NCT00211536
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic MiniMed Implantable Pump Human Recombinant Insulin, Medtronic MiniMed Implantable Pump System, Aventis HOE21PH U400
Drug · Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
5
States / cities
Santa Barbara, California • Aurora, Colorado • North Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 23, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome

NCT02165111
View directory record Official record
Conditions
Scleroderma, Raynaud's Syndrome
Interventions
Onabotulinumtoxin A, sterile saline solution
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 23, 2026, 8:55 AM EDT
Active, not recruiting Phase 2 Interventional

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

NCT05866536
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Diabetes type1, Autoimmune Diabetes
Interventions
Bacillus Calmette-Guérin, Saline Injection
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 23, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

NCT05463744
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes
Interventions
Insulin Efsitora Alfa, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
34
States / cities
Concord, California • Fresno, California • Montclair, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 23, 2026, 8:55 AM EDT
Completed Not applicable Interventional Results available

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B

NCT00858273
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Antioxidant supplement, Diabetes treatment, Regular Insulin
Dietary Supplement · Other · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 23, 2026, 8:55 AM EDT
Active, not recruiting Phase 3 Interventional

Avexitide for Treatment of Post-Bariatric Hypoglycemia

NCT06747468
View directory record Official record
Conditions
Post Bariatric Hypoglycemia
Interventions
Avexitide, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Stanford, California • Aurora, Colorado • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 23, 2026, 8:55 AM EDT
Terminated Phase 1 Interventional Results available

A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes

NCT02588950
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
U-500R
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 23, 2026, 8:55 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

NCT01966978
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes
Interventions
Metformin, Detemir, Liraglutide, Insulin Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 23, 2026, 8:55 AM EDT